In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cambridge Heart

This article was originally published in The Gray Sheet

Executive Summary

Microvolt level T-wave alternans measured with the firm's CH2000 test system "was the only statistically significant predictor of sudden death" among seven different clinical measures evaluated in a study of 107 congestive heart failure (CHF) patients followed for 18 months, the firm reports. Published in the Aug. 19 issue of The Lancet, the study included patients with no prior history of sustained ventricular arrhythmias. The study shows the technology to be "the most effective non-invasive test to identify [CHF] patients at risk for developing life-threatening abnormal heart rhythms," the firm maintains. The CH2000 system was cleared by FDA in 1996, and labeling was expanded in April 1999 to include the prediction of risk for severe cardiac arrest

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts